Vienna, Austria – May 9, 2026 – A groundbreaking study published today in the esteemed journal Cancers sheds new light on the prognostic capabilities of advanced imaging techniques in the fight against hepatocellular carcinoma (HCC), the third leading cause of cancer-related mortality globally. Researchers at the Medical University of Vienna have demonstrated that the metabolic activity of HCC, as visualized by [18F]-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) integrated with Magnetic Resonance Imaging (MRI), provides crucial information about patient survival, independent of traditional MRI findings and histological grading.
The study, spearheaded by Marzieh Nejabat and a multidisciplinary team, utilized a retrospective analysis of 25 patients with HCC who underwent contrast-enhanced PET/MRI scans employing dual tracers: 18F-FDG and [18F]-fluoroethylcholine (18F-FEC). This innovative approach allows for the simultaneous assessment of both glucose metabolism (18F-FDG) and cell membrane synthesis (18F-FEC), offering a comprehensive view of tumor biology.
Main Facts: 18F-FDG Emerges as a Key Prognosticator
The core finding of this research is the significant correlation between 18F-FDG uptake and patient survival. Specifically, higher standardized uptake values (SUVs) of 18F-FDG, a marker of increased glucose metabolism, were consistently associated with a poorer prognosis and shorter overall survival. This association was most pronounced with SUVmean and SUVpeak metrics.
In stark contrast, the 18F-FEC tracer, while showing a moderate correlation with alpha-fetoprotein (AFP) levels, a known tumor marker for HCC, did not demonstrate significant prognostic value in this cohort. This suggests that while 18F-FEC can aid in lesion characterization, it does not carry the same predictive weight as 18F-FDG regarding patient outcomes.
Furthermore, the study found that standard MRI enhancement parameters, often used to assess tumor vascularity, showed no significant correlation with survival. This highlights a critical limitation of conventional imaging in fully capturing the aggressive nature of HCC, underscoring the added value of metabolic imaging.
Chronology of Research and Findings
The research, conducted over an extended period, meticulously gathered data from patients who underwent integrated PET/MRI examinations. The study design involved:
- Patient Selection: A retrospective review of 25 patients with histologically confirmed HCC was conducted, excluding those with secondary malignancies or incomplete data.
- Imaging Protocol: All examinations utilized an integrated 3-Tesla PET/MRI scanner. Patients received intravenous injections of 18F-FDG followed by 18F-FEC. MRI protocols included dynamic contrast-enhanced sequences with gadoxetic acid.
- Image Analysis: PET images were analyzed for SUVmax, SUVmean, and SUVpeak, along with metabolic tumor volume (MTV). MRI images were assessed for enhancement patterns at early (3-5 minutes) and delayed (20-30 minutes) post-contrast phases.
- Correlation and Survival Analysis: Statistical analyses, including Spearman’s rank correlation, Kaplan-Meier survival analysis, and Cox proportional hazards models, were employed to evaluate the relationships between imaging parameters, histological grade, AFP levels, and overall survival.
The findings were systematically analyzed, revealing that 18F-FDG SUVmean demonstrated the strongest inverse association with survival (r = -0.61, p = 0.003), followed by SUVpeak (r = -0.50, p = 0.012). Kaplan-Meier analysis further solidified these results, showing significantly shorter survival in patients with high 18F-FDG SUVmean (log-rank p < 0.001).
A crucial sensitivity analysis focusing on patients who had not yet undergone treatment revealed that the prognostic association of 18F-FDG became even more pronounced, suggesting its utility for baseline risk stratification.
Supporting Data: Unpacking the Nuances
The study’s findings are supported by a robust dataset, including:
- Tumor Heterogeneity: The research acknowledges the inherent biological heterogeneity of HCC, where morphology and vascularity do not always mirror metabolic aggressiveness or histological grade. This heterogeneity is precisely what advanced metabolic imaging aims to elucidate.
- Histological Grade: While 18F-FDG SUVmean showed a significant trend across different tumor grades (G1-G3, p = 0.04), indicating higher uptake in more aggressive tumors, 18F-FEC did not exhibit such clear grade-dependent variations.
- Independent Predictors: In univariable Cox regression, 18F-FDG SUVpeak emerged as a significant predictor of shorter overall survival (HR 1.22, p = 0.01). This independent predictive power is a key takeaway, suggesting that 18F-FDG PET/MRI can offer prognostic insights beyond conventional assessments.
- Treatment Status Impact: The study noted a borderline association between post-treatment imaging and survival, suggesting that treatment status can influence the interpretation of imaging results, potentially affecting tracer uptake.
Official Responses and Clinical Implications
The implications of this research are far-reaching for the clinical management of HCC. While the study emphasizes that routine dual-tracer PET/MRI may not be cost-effective for all patients, it strongly advocates for its selective use in specific scenarios.
"Our findings underscore the critical role of 18F-FDG PET in understanding the aggressive potential of HCC," stated lead author Marzieh Nejabat. "This metabolic information, when integrated with MRI, provides a more comprehensive picture of tumor biology than MRI alone, enabling more accurate prognostication."
The researchers suggest that 18F-FDG-based metabolic imaging can enhance pre-treatment risk stratification. For patients with elevated AFP or indeterminate lesions on conventional imaging, dual-tracer PET/MRI could offer valuable diagnostic and prognostic information. This could lead to more tailored treatment strategies and improved patient outcomes.
Dr. Sazan Rasul, the corresponding author, added, "While 18F-FEC plays a role in lesion characterization, its prognostic value appears limited compared to 18F-FDG. The true power lies in combining these modalities to capture different facets of tumor behavior, particularly for challenging or high-risk cases."
Future Directions and Global Applicability
The study acknowledges its limitations, including its retrospective nature, single-center design, and relatively small sample size. However, the consistency of the findings and their alignment with existing literature provide a strong foundation for future research.
The authors call for larger, prospective studies to further validate these results and define the optimal role of 18F-FDG PET/MRI in the clinical management of HCC. The potential for this advanced imaging approach to influence treatment decisions, guide surveillance strategies, and ultimately improve patient survival is significant.
Globally, where integrated PET/MRI technology is increasingly available, these findings support a more nuanced approach to HCC imaging. The ability to gain deeper biological insights into tumor aggressiveness before initiating treatment could lead to more personalized and effective care for patients worldwide. The study concludes that while 18F-FDG PET/MRI shows promise for staging and prognostication, dual-tracer imaging should be considered a selective, exploratory tool rather than a routine diagnostic measure.
About the Author
